Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Sept. 11, 2024 – Social media platforms lit up minutes after the FDA announced its authorization of the updated Novavax COVID-19 vaccine right before Labor Day weekend. It was the last of three ...
Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for ... The deal with Sanofi breathes new life into ...
RSV and Meningitis / travel vaccines will be the COVID vaccine developed by Novavax (NVAX) - as I wrote in a recent note on Novavax: By the terms of the deal, Sanofi made a $500m upfront payment ...
Second, Novavax is getting ready to hand over the rights to its COVID-19 vaccine in most countries to Sanofi in 2025. That was part of their deal. Sanofi will also use Novavax's adjuvant ...
The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...
Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine ... licensing agreement which Novavax announced with healthcare giant Sanofi ...
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...